Maarten van den Buuse Selected Research

Dyskinesias (Dyskinesia)

1/2013	The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
12/2011	Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
12/2011	Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
11/2004	Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maarten van den Buuse Research Topics

Disease

73	Schizophrenia (Dementia Praecox) 04/2024 - 03/2003
25	Psychotic Disorders (Schizoaffective Disorder) 04/2024 - 04/2003
9	Mental Disorders (Mental Disorder) 12/2023 - 10/2004
5	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2023 - 10/2020
4	Bipolar Disorder (Manic Depressive Psychosis) 12/2023 - 03/2009
4	Alcoholism (Alcohol Abuse) 05/2023 - 02/2018
4	Mood Disorders (Mood Disorder) 01/2023 - 07/2014
4	Dyskinesias (Dyskinesia) 01/2013 - 11/2004
4	Parkinson Disease (Parkinson's Disease) 01/2013 - 11/2004
3	Substance-Related Disorders (Drug Abuse) 05/2023 - 02/2018
3	Inflammation (Inflammations) 01/2023 - 07/2011
3	Anxiety Disorders (Anxiety Disorder) 01/2023 - 12/2005
3	Ganglion Cysts (Ganglion) 10/2022 - 09/2014
3	Tachycardia (Tachyarrhythmias) 03/2003 - 02/2002
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 01/2018
2	Glaucoma 10/2022 - 09/2014
2	Cognitive Dysfunction 08/2020 - 12/2016
2	Memory Disorders (Memory Loss) 10/2017 - 06/2012
2	Dystonia (Limb Dystonia) 01/2013 - 12/2011
1	Trauma and Stressor Related Disorders 12/2023
1	Seasonal Affective Disorder 12/2023
1	Major Depressive Disorder (Major Depressive Disorders) 12/2023
1	Shock 01/2023
1	Paranoid Schizophrenia (Delusional Disorder) 11/2022
1	Anorexia 04/2022
1	Anorexia Nervosa 04/2022
1	Weight Loss (Weight Reduction) 12/2021
1	Fetal Growth Retardation (Intrauterine Growth Retardation) 10/2021
1	Silver-Russell Syndrome 10/2021
1	Pleomorphic Adenoma 10/2021
1	Autistic Disorder (Autism) 01/2021
1	Wounds and Injuries (Trauma) 10/2020
1	Body Weight (Weight, Body) 05/2020
1	Ketosis 05/2020

Drug/Important Bio-Agent (IBA)

35	Brain-Derived Neurotrophic Factor (BDNF)IBA 12/2023 - 04/2011
14	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 04/2024 - 02/2009
14	Methamphetamine (Desoxyn)FDA LinkGeneric 12/2023 - 12/2012
11	Antipsychotic Agents (Antipsychotics)IBA 12/2023 - 03/2003
10	Dopamine (Intropin)FDA LinkGeneric 01/2022 - 11/2004
9	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2023 - 04/2006
9	Serotonin (5 Hydroxytryptamine)IBA 01/2017 - 12/2003
8	Estrogens (Estrogen)FDA Link 01/2018 - 04/2006
6	N-Methylaspartate (NMDA)IBA 01/2022 - 02/2009
6	Amphetamine (Amfetamine)FDA LinkGeneric 01/2022 - 04/2003
5	Dizocilpine Maleate (Dizocilpine)IBA 04/2024 - 06/2012
5	Psychotropic Drugs (Psychoactive Drugs)IBA 01/2023 - 12/2003
5	Nerve Growth Factors (Neurotrophins)IBA 10/2022 - 04/2011
5	CorticosteroneIBA 08/2014 - 02/2002
4	Proteins (Proteins, Gene)FDA Link 01/2023 - 04/2011
4	Glutamic Acid (Glutamate)FDA Link 09/2017 - 07/2011
4	5-HT1A Serotonin ReceptorIBA 01/2017 - 04/2006
4	Levodopa (L Dopa)FDA LinkGeneric 01/2013 - 11/2004
3	Messenger RNA (mRNA)IBA 01/2023 - 01/2015
3	Phencyclidine (Angel Dust)IBA 01/2022 - 01/2013
3	Apomorphine FDA Link 01/2018 - 07/2011
3	Hormones (Hormone)IBA 12/2016 - 06/2004
3	Glutathione (Reduced Glutathione)IBA 07/2011 - 03/2009
2	Selective Estrogen Receptor Modulators (SERM)IBA 04/2024 - 11/2015
2	Raloxifene Hydrochloride (Evista)FDA Link 04/2024 - 01/2018
2	Dopamine Receptors (Dopamine Receptor)IBA 12/2023 - 01/2018
2	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 12/2023 - 01/2015
2	methionylmethionine (Met-Met)IBA 12/2023 - 05/2023
2	Phosphotransferases (Kinase)IBA 10/2022 - 01/2021
2	Amyloid (Amyloid Fibrils)IBA 10/2022 - 09/2014
2	Retinaldehyde (Retinal)IBA 10/2022 - 09/2014
2	TropomyosinIBA 10/2022 - 01/2021
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2021 - 01/2021
2	ParvalbuminsIBA 01/2021 - 07/2014
2	Glucose (Dextrose)FDA LinkGeneric 05/2020 - 01/2019
2	Therapeutic UsesIBA 05/2020 - 01/2018
2	Ethanol (Ethyl Alcohol)IBA 05/2020 - 02/2018
2	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2020 - 01/2015
2	Serotonin ReceptorsIBA 01/2018 - 01/2017
2	Clonidine (ST 155)FDA LinkGeneric 01/2016 - 01/2013
2	Neurotransmitter Agents (Neurotransmitter)IBA 12/2012 - 03/2010
2	AntioxidantsIBA 12/2010 - 12/2010
2	Clozapine (Clozaril)FDA LinkGeneric 02/2009 - 03/2003
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 12/2023
1	MetergolineIBA 12/2023
1	AlkaloidsIBA 12/2023
1	Dopamine D3 ReceptorsIBA 08/2023
1	MicroRNAs (MicroRNA)IBA 01/2023
1	NeuregulinsIBA 01/2023
1	trkB ReceptorIBA 10/2022
1	Designer DrugsIBA 12/2021
1	Transcription Factors (Transcription Factor)IBA 10/2021
1	6,7-dihydroxyflavoneIBA 01/2021
1	ProteomeIBA 01/2021
1	Antidepressive Agents (Antidepressants)IBA 10/2020
1	3-Hydroxybutyric Acid (beta-Hydroxybutyric Acid)IBA 05/2020
1	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA 01/2020
1	Poly I-CIBA 01/2020
1	Olanzapine (Zyprexa)FDA Link 10/2019
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2019
1	CarbohydratesIBA 01/2019
1	Huntingtin ProteinIBA 01/2018
1	Dopamine Agonists (Dopamine Agonist)IBA 01/2018

Therapy/Procedure

3	Ketogenic Diet 05/2020 - 01/2019
2	Ovariectomy (Oophorectomy) 10/2017 - 01/2014
1	Self Administration (Administration, Self) 01/2019